Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
RAPT

RAPT - RAPT Therapeutics Inc Stock Price, Fair Value and News

$57.610.00 (0.00%)
Market Closed

10/100

RAPT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

10/100

RAPT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$46.1

Target 3M

$51.87

Target 6M

$48.99

RAPT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RAPT Price Action

Last 30 days

60.7%

Last 90 days

94.0%

Trailing 12 Months

510.3%

RAPT RSI Chart

RAPT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RAPT Valuation

Market Cap

1.6B

Price/Earnings (Trailing)

-15.11

Price/Sales (Trailing)

525.36

EV/EBITDA

-11.2

Price/Free Cashflow

-18.42

RAPT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$46.1

Target 3M

$51.87

Target 6M

$48.99

RAPT Fundamentals

RAPT Revenue

Revenue (TTM)

1.5M

RAPT Earnings

Earnings (TTM)

-105.6M

Earnings Growth (Yr)

4.62%

Earnings Growth (Qtr)

0.36%

RAPT Profitability

EBT Margin

-4532.02%

Return on Equity

-69.51%

Return on Assets

-63.74%

Free Cashflow Yield

-5.43%

RAPT Investor Care

Shares Dilution (1Y)

534.15%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20223.2M3.2M2.3M1.5M
20215.3M4.9M4.4M3.8M
20200005.0M
Get all data in R, Python etc through our Historical Stock Data APIs

About RAPT Therapeutics Inc

RAPT
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
 CEO
 WEBSITErapt.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES122

RAPT Therapeutics Inc Frequently Asked Questions

RAPT is the stock ticker symbol of RAPT Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of RAPT Therapeutics Inc is 1.6 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check RAPT's fair value in chart for subscribers.

The fair value guage provides a quick view whether RAPT is over valued or under valued. Whether RAPT Therapeutics Inc is cheap or expensive depends on the assumptions which impact RAPT Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RAPT.

As of Wed Jan 28 2026, RAPT's PE ratio (Price to Earnings) is -15.11 and Price to Sales (PS) ratio is 525.36. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RAPT PE ratio will change depending on the future growth rate expectations of investors.